The Next Biotechnology

A sophisticated investor's practical tool kit for analyzing the science, business, opportunities, and risks in the century's most promising industry The world is entering a biotechnology boom-but only informed investors will prosper in the incredibly complex biotech business. Separating the bioengineered wheat from the chaff, San Francisco Chronicle science and technology columnist Tom Abate, one of the top objective authorities on biotech, gives investors the analytical foundation to understand the science, finances, time horizon, and technological and commercial potential of this burgeoning industry. In The Biotech Investor, Abate provides sophisticated business analysis, guidelines for assessing company leadership, easy-to-digest reports from the labs, and indispensable investor tools and metrics. He explains how breaking news, medical conferences, U.S. Food and Drug Administration approvals, and the patent process affect investing strategies. Finally, he looks beyond medicine to review the financial opportunities presented by biotechnology advances in everything from agriculture to jean manufacturing, and shows investors how to identify "coattail" industries such as instrumentation and software development that will benefit from biotech successes. The Biotech Investor is the comprehensive, expert source for successful and intelligent investing in one of the twenty-first century's most promising industries.

"The biotech industry is a complex, rapidly evolving, and critical industry. The industry holds great commercial and societal promise, but it is also filled with hype, confusion, and risks. Bergeron and Chan do a remarkable job of providing a sweeping insightful, and probing assessment of the current state and likely evolution of this global industry. This book is essential reading for the executive who desires a thorough understanding of this business and its potential."--John P. Glasser, Vice President and Chief Information Offers, Partners Healthcare System, Inc. "Bergeron and Chan have done a marvelous job integrating many different perspectives to give the reader a coherent road map of the biotech industry for the next decade. This powerful book is anchored by numerous relevant examples that create a framework which any life sciences professional needs to understand. Of particular note is the compelling assessment of the IT industry and its impact on the life sciences as these industries converge."--Michael A. Greeley, Managing General Partner, IDG Ventures. An in-depth examination of the growth and financing of the biotechnology industry worldwide Biotech Industry: A Global, Economic, and Financing Overview provides a thorough look at the current state of the biotechnology industry, including where major research is being conducted, where it's being applied, and where money and intellectual capital are flowing. Written by a renowned business columnist and an entrepreneurial scientist in the biotech area, this unique book gives Eos and other senior-level managers an understanding of Asia's pivotal role in the worldwide success of biotechnology commercialization, as well as insight into the biotech market over the next decade.

"Beginning in the 1970s, several scientific breakthroughs promised to transform the creation of new medicines. As investors sought to capitalize on these Nobel Prize-winning discoveries, the biotech industry grew to thousands of small companies around the world. Each sought to emulate what the major pharmaceutical companies had been doing for a century or more, but without the advantages of scale, scope, experience, and massive resources. How could a large collection of small companies, most with fewer than 50 employees, compete in one of the world's most breathtakingly expensive and highly regulated industries? This book shows how biotech companies have met the challenge by creating nearly 40% more of the most important treatments for unmet medical needs. Moreover, they have done so with much lower overall costs. The book focuses on both the companies themselves and the broader biotech ecosystem that supports them. Its portrait of the crucial roles played by academic research, venture capital, contract research organizations, the capital markets, and pharmaceutical companies shows how a supportive environment enabled the entrepreneurial biotech industry to create novel medicines with unprecedented efficiency. In doing so, it also offers insights for any industry seeking to innovate in uncertain and ambiguous conditions. Looking to the future, it concludes that biomedical research will continue to be most effective in the hands of a large group of small companies as long as national healthcare policies allow the rest of the ecosystem to continue to thrive"--

Welcome to the biotech revolution In the last century, technology has transformed the human experience across the world. This has been super-charged by the arrival of the internet, smart phones, AI and machine learning, and created trillion-plus dollar companies and household names like Apple, Amazon, Google and Microsoft. Our Future is Biotech explains why biotech is next: because our biggest remaining challenges as a species concern biological systems. Biotech companies will solve our most intractable problems, from cancer, dementia, obesity and diabetes to elderly care, mental health conditions, and even power generation, agricultural production and environmental degradation. Biotech means that we will live better, safer, healthier, wealthier, happier, and longer lives. The industry has already delivered "miracle cures" for several diseases, and there is more to come. But despite this, few people are aware of the phenomenal progress being made. Our Future is Biotech addresses this, explaining what biotech is, what is coming next, and how you might profit from it too. Tech has been the most important theme for human progress for the last century. Biotech is next.

The Apples, Amazons and Googles of the next few decades will be biotech companies. The tech companies of the last few years have changed how we do things but the businesses driving the biotech revolution are about making life better.

A look at the forefront of an industry revolution "I've been deep inside the biotech industry since its infancy. This book provides fresh insights about how it started, what drives it, and most importantly, where it's going."--Scott W. Morrison, partner, Ernst & Young LL Richard W. Oliver predicted the onset of a new era with The Coming Biotech Age. Now that age is here--and companies are reaping the benefits of this incredible new revolution. As biotech companies become the new economic engines of growth and innovation, businesses must have access to the latest developments of this area of research. In a special revised edition, now titled The Biotech Age, Oliver has created the first practical guide to this fascinating realm of scientific development. With updated information on the latest research, examples of biotech breakthroughs, and a close examination of current biotech issues such as cloning and stem cell research, The Biotech Age presents an accessible overview of the business of biotechnology and its vast implications and opportunities for all types of industries. This is a topic no one can afford to miss--especially future-minded executives and investors in cutting-edge technologies.

An essential guide for students in the life sciences, established researchers, and career counselors, this resource features discussions of job security, future trends, and potential career paths. Even those already working in the industry will find helpful information on how to take advantage of opportunities within their own companies and elsewhere.